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Alexis Tsorbatzoglou, MD, PhD, Bo Philipson, MD, PhD, Carlo E. Traverso, MD, Harvey Reiser, MDQ 2013 A
PublishedSCRS an
by ElsevPURPOSE: To evaluate once-daily nepafenac 0.3% to prevent and treat ocular pain and
inflammation after cataract surgery.
SETTING: Sixty-five centers in the United States and Europe.
DESIGN: Randomized double-masked vehicle- and active-controlled phase 3 study.
METHODS: Patients received nepafenac 0.3% once daily, nepafenac 0.1% 3 times daily, or their
respective vehicles from day 1 to day 14 after cataract extraction. An additional drop of study
drug was administered 30 to 120 minutes preoperatively. The primary endpoint was the percentage
of patients with a cure for inflammation (score of 0 for both aqueous cells and flare) at day 14.
RESULTS: Of randomized patients, 817 received nepafenac 0.3%, 819 received nepafenac 0.1%,
and 200 and 206 received the respective vehicles. Significantly more nepafenac 0.3% patients
had no inflammation (68.4% versus 34.0%) and were pain free (91.0% versus 49.7%) at day 14
than vehicle patients (both P<.0001). Nepafenac 0.3% was noninferior to nepafenac 0.1% for
inflammation (95% confidence interval [CI], 5.73% to 3.17%) and pain-free rates (95% CI,
3.08% to 2.70%). At all postoperative visits, fewer treatment failures (P%.0012) and more
clinical successes (P%.0264) were observed with nepafenac 0.3% versus vehicle. Nepafenac
0.3% was well tolerated and had a safety profile comparable to that of nepafenac 0.1%.
CONCLUSIONS: Once-daily nepafenac 0.3% was noninferior to nepafenac 0.1% 3 times daily for
prevention and treatment of ocular inflammation and pain following cataract surgery. The safety
of nepafenac 0.3% was comparable to that of nepafenac 0.1%, with the added convenience of
once-daily dosing.
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J Cataract Refract Surg 2014; 40:203–211 Q 2013 ASCRS and ESCRSCataract is the leadingcauseofblindnessworldwideand
the main cause of reversible decreased vision in the
elderly in the developedworld.1,2 Patientswith cataracts
have a gradual loss in visual acuity that may be accom-
panied by reduced physical ability and loss of self-
esteem, creating a considerable social and economic
burden.3,4 In developed countries, cataract surgery is
oneof themost commonsurgicalproceduresperformed.
Overall, its high success rates yield improved visual
acuity and improved patient quality of life.1,5,6 Wider
ranging positive effects include a reduced risk for hipd ESCRS
ier Inc.fractures in patients who have had cataract surgery
compared with matched cataract patients who have
not had surgery.7 As the mean and median age of the
world population increases, the prevalence of cataracts
and the number of patients in need of cataract surgery
will steadily increase worldwide.1
Intraocular inflammation is a common event after
cataract surgery. It is often managed with corticoste-
roid and topical antiinflammatory agents to reduce
symptoms, increase comfort, and prevent complica-
tions.8,9 The inflammatory process is mediated by the0886-3350/$ - see front matter 203
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the subsequent production of proinflammatory pros-
taglandins.8,10 Prostaglandins have in turn been linked
to disruption of the blood–aqueous barrier and in-
creases in vascular permeability changes associated
with inflammation and edema.11,12 Nonsteroidal anti-
inflammatory drugs (NSAIDs) are potent inhibitors
of COX enzymes and prostaglandin production. The
efficacy and safety of topical NSAIDs in treating
postsurgical ocular inflammation and pain are well
established, and the relative merits and risks of
NSAIDs versus postoperative topical steroids have
been addressed by several authors.8,10
Nepafenac ophthalmic suspension 0.1% (nepafenac
0.1%) (Nevanac) is a topical ocular NSAID used to pre-
vent and treat the pain and inflammation associated
with cataract surgery.13,A In contrast to other ocular
NSAIDs, nepafenac is a prodrug that rapidly pene-
trates the cornea and is deaminated by intraocular
hydrolases within ocular tissues to form the active
metabolite amfenac.13,A Nepafenac and amfenac are
potent inhibitors of the COX enzymes COX-1 and
COX-2.14,15 The bioconversion of nepafenac is greatest
in vascularized tissues, such as the iris and ciliary body
and, to a greater extent, the retina and choroid,15
the region of the eye with the greatest prostaglandin
concentrations and COX activity.16
Clinical studies13,17–19 have shown that nepafenac
0.1% taken 3 times daily beginning the day before sur-
gery is well tolerated and effective in the treatment of
the ocular inflammation and pain associated withSubmitted: June 11, 2013.
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J CATARACT REFRACT SURG - Vcataract surgery. Furthermore, recent studies20,21
have found that nepafenac 0.1% is effective in reducing
macular edema secondary to cataract extraction and
macular edema associated with diabetes. Nepafenac
0.1% is approved by the European Medicines Agency
but not by the United States Food and Drug Adminis-
tration to reduce the risk for macular edema that can
occur after cataract surgery in patients with diabetes.B
A new formulation of nepafenac ophthalmic suspen-
sion (nepafenac 0.3%) that can be used once a day to pre-
vent and treat ocular inflammation and pain after
cataract surgery has been developed and recently
approved for use in the U.S.C In addition to its higher
concentration of the active molecule, nepafenac 0.3%
has a reduced particle size compared with nepafenac
0.1%, which increases the surface area for dissolution,
and added guar, a retention agent that enhances the
bioavailability of nepafenac in the eye over that with ne-
pafenac 0.1%. Here, we report the results of a phase 3
study that evaluated the safety and efficacyof nepafenac
0.3% taken once daily relative to nepafenac 0.1% 3 times
daily and the respective vehicles for the prevention and
treatment of ocular inflammation and pain 14 days after
cataract extraction.PATIENTS AND METHODSStudy DesignThis randomized double-masked parallel-group multi-
center vehicle- and active-controlled phase 3 study was per-
formed at 65 centers in Europe (Hungary, Italy, Sweden,
and Switzerland) and the United States between June 2010
and May 2011. Eligible patients were randomized (4:4:1:1)
to receive nepafenac 0.3% once daily, nepafenac 0.1% 3 times
daily, or their respective vehicles.
The study consisted of 6 visits as follows: a screening/base-
line visit (performed within 2 days to 6 weeks before the
surgery visit), the cataract surgeryvisit (day 0), and 4 postoper-
ative visits (days 1, 3, 7, and 14). Patients began instilling the
study drugddosed once daily if assigned to nepafenac 0.3%
or its vehicle or 3 times daily if assigned to nepafenac 0.1%
or its vehicledinto the study eye on the day before cataract
surgery (day 1). Dosing continued on the day of surgery
(day 0) and for 14 days thereafter. On the day of surgery,
designated study personnel instilled 1 additional drop of the
assigned study drug into each patient's study eye 30 to 120mi-
nutes before surgery. All patients received the investigator's
standard regimen of preoperative, intraoperative, and postop-
erative carewith the exception ofNSAID and steroid use. Dur-
ing the study, all patients, investigators, and study-related
personnel were masked to the treatment assignment, and all
personnel involved in efficacy assessments and analysis of re-
sults were masked to the dosing frequency.
The studywas performed in accordancewithGoodClinical
Practices and the ethical principles described in
the Declaration of Helsinki. An institutional review board/in-
dependent ethics committee in each associated country
approved the protocol. On entry, all participating patients
provided written informed consent. This study is registered
at clinicaltrials.gov as NCT01109173.DOL 40, FEBRUARY 2014
205NEPAFENAC 0.3% TO PREVENT AND TREAT OCULAR INFLAMMATION AND PAIN ASSOCIATED WITH CATARACT SURGERYPatientsMale and female patients aged 18 years or olderwho had a
planned cataract extraction by phacoemulsification with the
implantation of a posterior chamber intraocular lens (IOL)
were eligible for inclusion. Patients who had a history of
ocular surgery, inflammatory eye disease, ocular infection,
congenital ocular anomalies, uncontrolled glaucoma, dia-
betic retinopathy, and ocular trauma or current signs and
symptoms that were associated with these or other ocular
conditions were excluded. Additional exclusion criteria
were planned multiple procedures for the study eye during
cataract extraction and IOL implantation, use of steroids by
any route within 14 days of surgery, and use of NSAIDs
by any route within 7 days of surgery (except an allowed
daily dose of 100 mg aspirin). Use of steroids and other
topical ocular or systemic NSAIDs was also prohibited for
the duration of the study.Endpoints and AssessmentsEfficacy All patients were evaluated for efficacy and safety
on days 1, 3, 7, and 14 or at the time of earlier discontinuation
from the study. The primary efficacy endpoint was the
percentage of patients at day 14 whose inflammation had
resolved (considered cured), defined as a score of 0 for
aqueous cells and flare. Ocular inflammation (cells and flare)
was assessed by the investigators at the screening/baseline
visit and at all postoperative visits using slitlamp bio-
microscopy. Inflammatory cells were graded using a scale
that ranged from 0 (none) to 4 (more than 30 cells). Flare
was graded using a scale that ranged from 0 (no visible flare
comparedwith the normal eye) to 3 (severe; very dense flare).
The secondary efficacy endpoint was the percentage of
patients who were pain free at day 14, defined as an ocular
pain assessment score of 0. Ocular pain was assessed by pa-
tient reports to the investigators at the screening/baseline visit
andat allpostoperativevisits.Ocularpainwasdocumentedus-
ing a categorical scale that ranged from 0 (none) to 5 (severe).
In addition to the primary and secondary endpoints, a
series of prespecified supportive efficacy endpoints were
included as follows: the percentage of cumulative cures by
visit (resolution of inflammation by visit) (ie, the percentage
of patients who met the definition of a cure at each visit and
remained cured at all subsequent visits), the cumulative
pain-free rates by visit (ie, the percentage of patients who
met the definition of pain free at each visit and remained
pain free at all subsequent visits), and the percentage of
patients who were declared treatment failures at each visit.
A patient was classified as a treatment failure if he or she
had an aqueous cells score of 3 or higher, an aqueous flare
score of 3, and/or an ocular pain score of 4 or higher.
The percentage of patients in each treatment group
who achieved clinical success was evaluated as a planned
exploratory analysis of the primary variable. For this anal-
ysis, clinical success was defined as a cells score of 1 or less
(0 to 5 cells) and a flare score of 0.
Safety Information on adverse events was collected for all
patients after the first administration of study drug on day
1 and continued through day 14 (or early exit). All reported
and observed adverse events were assessed according
to their seriousness, severity (mild, moderate, or severe),
relationship to the study drug, individual characteristics
(eg, onset, duration, and outcome), and whether they
resulted in patient discontinuation from the study.J CATARACT REFRACT SURG - VIn addition to a review of reported adverse events, the
safety of nepafenac 0.3%was assessedby routine ocular exam-
inations. Specifically, the safety review included intraocular
pressure (IOP)measurements, other ocular outcomes (chemo-
sis, bulbar conjunctival injection, corneal edema) derived
from slitlamp biomicroscopy evaluations, dilated fundus
parameters (retina/macula/choroid, optic nerve), and results
of corrected distance visual acuity (CDVA) assessments.Statistical AnalysisEfficacy analyses were performed with the intent-to-treat
analysis set, which included all randomized patients who
received the study drug and had at least 1 on-therapy post-
surgical visit. Safety was evaluated for all patients who
received exposure to the study drug or potential exposure
to the study drug (ie, patients who discontinued the study
before surgery but returned an opened bottle of study
drug or failed to return the study drug).
A sample size of 800 patients in each of the nepafenac
groups and 200 patients in each of the corresponding vehicle
groups was calculated to provide a statistical power of 98%
to show nepafenac 0.3% instilled once daily was noninferior
to nepafenac 0.1% instilled 3 times daily and a statistical
power of 99% to show superiority of nepafenac 0.3% and
nepafenac 0.1% compared with their respective vehicles in
terms of the proportion of patients who achieve a clinical
cure. The cure rate in the nepafenac groups and vehicle
groups was assumed to be 70% and 50%, respectively.
Testing to determine whether nepafenac 0.3% was as effec-
tive as nepafenac 0.1% used the 2-sided 95% confidence
interval (CI) approach derived from the method of
Yanagawa et al.22 The noninferiority margin was 10%;
thus, to show that nepafenac 0.3% was as effective as nepa-
fenac 0.1%, the lower limit of the 2-sided 95% CI had to be
greater than 10%. Pairwise superiority testing for compar-
isons of each active treatment to their respective vehicles was
performed using the 2-sided Cochran-Mantel-Haenszel test
controlling for investigational center with a significance
level of 0.05. Supportive endpoints were described using
summary statistics by treatment group and visit.
To ensure the type 1 error rate was controlled at the 5%
level, a gate-keeping multiplicity strategy was used. All 3
co-primary hypotheses must be rejected for a successful
study, and conclusion from the 3 secondary endpoint hypo-
theses was only possible after rejection of the primary
endpoint hypotheses. In addition, successful conclusion of
the investigator assessment of ocular pain was possible only
if all 3 hypotheses were rejected and the primary endpoint
wasmet.Multiplicity adjustmentwas not applied on the sup-
portive endpoints. All statistical analyses were performed
using SAS software (version 9.2, SAS Institute, Inc.).
RESULTSPatient Characteristics and DispositionOf the 2120 patients enrolled in the study, 78 were
excluded fromthe safetypopulations (nZ2042) because
they did not receive study medication. A further 20 pa-
tients were dispensed study medication but discon-
tinued on the day of surgery and had no on-therapy
follow-up efficacy data collected. The intent-to-treat
population comprised 2022 patients who received
study medication and had at least 1 on-therapyOL 40, FEBRUARY 2014
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discontinuation was treatment failure (190 patients
[9.0%]) followed by non-use of studymedication (78 pa-
tients [3.7%]) and adverse events (47 patients [2.2%]).
Discontinuation due to treatment failure was similar be-
tween the 2 nepafenac treatment groups (nZ 25 [2.9%]
and nZ 32 [3.8%] for nepafenac 0.3% and 0.1%, respec-
tively) and between the 2 vehicle groups (nZ 69 [32.7%]
and nZ 64 [30.0%], respectively).
The distribution of demographic and baseline char-
acteristics were well balanced, with no clinically rele-
vant differences between groups (Table 1). The
majority of patients were 65 years of age or older,
women, and white.EfficacyOcular Inflammation Table 2 shows an analysis of
ocular inflammation and the absence of ocular pain
at 14 days in the intent-to-treat population. The
lower boundary of the 95% CI calculated from the
difference in the percentage of patients achieving
cure at day 14 was 5.73%. Thus, based on a
prespecified margin of 10%, nepafenac 0.3%
instilled once daily was noninferior to nepafenac
0.1% instilled 3 times daily for the prevention and
treatment of ocular inflammation 14 days after
cataract extraction.Table 1. Demographic and baseline characteristics, intent-to-treat popu
Parameter
Nepafenac 0.3%
(nZ 807)
Nepafenac 0.1%
(nZ 813)
Age (y)
MeanG SD 68.7G 9.08 68.8G 9.31
Range 32, 89 20, 90
Age Category, n (%)
!65 years 233 (28.9) 220 (27.1)
R65 years 574 (71.1) 593 (72.9)
Sex, n (%)
Male 342 (42.4) 355 (43.7)
Female 465 (57.6) 458 (56.3)
Race, n (%)
White 708 (87.7) 702 (86.3)
Black or African American 59 (7.3) 59 (7.3)
Asian 36 (4.5) 48 (5.9)
American Indian/Alaska Native 1 (0.1) 0
Multiracial 1 (0.1) 2 (0.2)
Other 2 (0.2) 2 (0.2)
Iris color, n (%)
Brown 379 (47.0) 373 (45.9)
Hazel 105 (13.0) 97 (11.9)
Green 67 (8.3) 61 (7.5)
Blue 236 (29.2) 267 (32.8)
Gray 14 (1.7) 12 (1.5)
Other 6 (0.7) 3 (0.4)
J CATARACT REFRACT SURG - VSignificantly more patients in the nepafenac 0.3%
and nepafenac 0.1% groups than patients in the respec-
tive vehicle groups achieved a cure at day 14 (both
P!.0001) (Table 2). Thus, both nepafenac groups
were superior to their respective vehicles for the
prevention and treatment of ocular inflammation
14 days after cataract extraction.
From day 7, the observed cumulative percentage of
patients who were cured in the nepafenac 0.3% group
was higher than in the nepafenac 0.3% vehicle group
(P!.0001 for pairwise comparisons at day 7 and day
14) (Figure 1). The percentage of patients cured was
also higher in the nepafenac 0.1% group than in the ne-
pafenac 0.1% vehicle group beginning at postopera-
tive day 3 (P!.0001 for pairwise comparisons at
days 3, 7, and 14).
Ocular Pain The lower boundary of the 95% CI calcu-
lated from the difference in the percentage of patients
in each group who were pain free was 3.08%
(Table 2), showing that nepafenac 0.3% once daily
was noninferior to nepafenac 0.1% 3 times daily for
the prevention and treatment of ocular pain 14 days
after cataract extraction.
Significantly more patients in the nepafenac 0.3%
and nepafenac 0.1% groups were pain free at day 14
than patients in the respective vehicle groups (both
P!.0001) (Table 2). Thus, each active treatment waslation.
Nepafenac 0.3% Vehicle
(nZ 197)
Nepafenac 0.1% Vehicle
(nZ 205)
Total
(nZ 2022)
69.8G 9.31 68.9G 9.37 68.9G 9.22
38, 92 38, 90 20, 92
51 (25.9) 55 (26.8) 559 (27.6)
146 (74.1) 150 (73.2) 1463 (72.4)
79 (40.1) 90 (43.9) 866 (42.8)
118 (59.9) 115 (56.1) 1156 (57.2)
170 (86.3) 175 (85.4) 1755 (86.8)
17 (8.6) 17 (8.3) 152 (7.5)
10 (5.1) 12 (5.9) 106 (5.2)
0 0 1 (0.0)
0 1 (0.5) 4 (0.2)
0 0 4 (0.2)
83 (42.1) 93 (45.4) 928 (45.9)
26 (13.2) 23 (11.2) 251 (12.4)
15 (7.6) 13 (6.3) 156 (7.7)
70 (35.5) 73 (35.6) 646 (31.9)
1 (0.5) 2 (1.0) 29 (1.4)
2 (1.0) 1 (0.5) 12 (0.6)
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Table 2. Analysis of ocular inflammation and absence of ocular pain at day 14 in the intent-to-treat population.
Parameter Nepafenac 0.3% (NZ 807) Nepafenac 0.1% (NZ 811)*
Nepafenac 0.3% Vehicle
(NZ 197)
Nepafenac 0.1% Vehicle
(NZ 205)
Ocular inflammation
Cured, n (%) 552 (68.4) 568 (70.0) 67 (34.0) 73 (35.6)
95% CI† 5.73, 3.17 d d
P value d d !.0001z !.0001x
Ocular pain
Pain free, n (%) 734 (91.0) 737 (90.9) 98 (49.7) 115 (56.1)
95% CI† 3.08, 2.70 – –
P value d d !.0001z !.0001x
CIZ confidence interval; CuredZ inflammation resolved
*Two patients were randomized but did not have on-study data
†Test-based CI for the difference in treatment percentages (nepafenac 0.3% minus nepafenac 0.1%)
zNepafenac 0.3% versus nepafenac 0.3% vehicle
xNepafenac 0.1% versus nepafenac 0.1% vehicle
207NEPAFENAC 0.3% TO PREVENT AND TREAT OCULAR INFLAMMATION AND PAIN ASSOCIATED WITH CATARACT SURGERYsuperior to its respective vehicle for the prevention
and treatment of ocular pain 14 days after cataract
extraction.
The cumulative percentage of patients who were
pain free in the nepafenac 0.3% and nepafenac 0.1%
groups was higher than in their respective vehicle
groups at all postoperative visits from day 1 through
day 14 (P!.0001 for all pairwise comparisons at
each study visit) (Figure 2).Clinical Success RatesThe cumulative clinical success rate at day 14 was
85.6% in the nepafenac 0.3% once daily (n Z 691)Figure 1. Percentage of cumulative cures by visit (intent-to-treat
population). For once-daily nepafenac 0.3%, n Z 804 at day 1 and
n Z 807 at all subsequent visits; for nepafenac 0.1% 3 times daily,
n Z 811 at all visits; for nepafenac 0.3% vehicle, n Z 196 at day 1,
and nZ 197 at all subsequent visits; and for nepafenac 0.1% vehicle,
n Z 205 at all visits (* Z significant difference between nepafenac
0.3% and nepafenac 0.3% vehicle [P!.0001]; **Z significant differ-
ence between nepafenac 0.1% and nepafenac 0.1% vehicle
[P!.0001]).
J CATARACT REFRACT SURG - Vand nepafenac 0.1% 3 times daily (n Z 694) groups;
the rates were 43.1% (n Z 85) and 47.8% (n Z 98) in
the respective vehicle groups. The cumulative percent-
age of patients whowere clinical successes was greater
in the nepafenac 0.3% group than in the nepafenac
0.3% vehicle group at all postoperative visits
(PZ.0264 at day 1; P!.0001 at days 3, 7, and 14).
The percentage of clinical successes was greater in
the nepafenac 0.1% group than in the nepafenac 0.1%
vehicle group on days 1, 3, 7, and 14 (P!.0001 at all
timepoints except day 1) (Figure 3).
The cumulative percentage of patients assessed as
treatment failures in the nepafenac 0.3% and nepafe-
nac 0.1% groups was lower than in the respectiveFigure 2. Cumulative percentage of patients pain free by visit
(intent-to-treat population). For once-daily nepafenac 0.3%, n Z
804 at day 1 and n Z 807 at all subsequent visits; for nepafenac
0.1% 3 times daily, nZ 811 at all visits; for nepafenac 0.3% vehicle,
nZ 196 at day 1 and nZ 197 at all subsequent visits; and for nepa-
fenac 0.1% vehicle, n Z 205 at all visits (* Z significant difference
between nepafenac 0.3% and nepafenac 0.3% vehicle [P!.0001];
** Z significant difference between nepafenac 0.1% and nepafenac
0.1% vehicle [P!.0001]).
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Figure 3. Cumulative percentage of patients considered clinical suc-
cesses by visit (intent-to-treat population). For once-daily nepafenac
0.3%, n Z 804 at day 1 and n Z 807 at all subsequent visits; for
nepafenac 0.1% 3 times daily, n Z 811 at all visits; for nepafenac
0.3% vehicle, nZ 196 at day 1 and nZ 197 at all subsequent visits;
and for nepafenac 0.1% vehicle, nZ 205 at all visits (*Z significant
difference between nepafenac 0.3% and nepafenac 0.3% vehicle
[P%.0264]; ** Z significant difference between nepafenac 0.1%
and nepafenac 0.1% vehicle [P!.0001]).
Figure 4. Treatment failures by visit (intent-to-treat population). For
once-daily nepafenac 0.3%, n Z 807; for nepafenac 0.1% 3 times
daily, nZ 811; for nepafenac 0.3% vehicle, n Z 205; and for nepa-
fenac 0.1% vehicle, n Z 205 (* Z significant difference between
nepafenac 0.3% and nepafenac 0.3% vehicle [P%.0012]; **Z signif-
icant difference between nepafenac 0.1% and nepafenac 0.1% vehicle
[P%.0006]).
208 NEPAFENAC 0.3% TO PREVENT AND TREAT OCULAR INFLAMMATION AND PAIN ASSOCIATED WITH CATARACT SURGERYvehicle groups at all postoperative visits (P%.0012 in
each pairwise comparison for every study visit)
(Figure 4).SafetyOverall, once-daily nepafenac 0.3% was well toler-
ated by patients. Across the treatment groups, 253
patients (12.4%) reported an adverse event during
the study. Of these, 3 patients were considered byTable 3. Adverse event characteristics and key adverse events (safety p
Parameter
Nepafenac 0.3%
(nZ 817)
Nepafena
(nZ
Patients with at least 1 TEAE 99 (12.1) 82 (10
Patients with any nonfatal SAE 7 (0.9) 3 (0
Discontinuations due to AE 15 (1.8) 17 (2
Discontinuations due to nonfatal SAE 2 (0.2) 2 (0
Related to treatment 0 0
Discontinuations due to nonfatal SAE 13 (1.6) 15 (1
Related to treatment 1 (0.1) 0
Most frequent AEs*
Headache 22 (2.7) 13 (1
IOP increase 8 (1.0) 7 (0
TEAE related to treatment
Eye pain 1 (0.1) 0
Hypersensitivity† 1 (0.1) 0
AEZ adverse event; IOPZ intraocular pressure; SAEZ serious adverse event; T
*Reported forR1% of patients in either active treatment group
†Led to patient discontinuation from study
J CATARACT REFRACT SURG - Vthe investigators to have experienced an adverse event
related to treatment (Table 3). All 3 events were nonse-
rious, were of mild to moderate intensity, and resolved
with orwithout treatment. One patient in the nepafenac
0.3% group who reported hypersensitivity to the study
drug discontinued the study. The remaining 2 events
involved eye pain (1 in the nepafenac 0.3% group and
1 in the nepafenac 0.1% vehicle group).
In total, 47 patients discontinued the study due to
nonserious adverse events (Table 3). With theopulation).
Number (%)
c 0.1%
819)
Nepafenac 0.3% Vehicle
(nZ 201)
Nepafenac 0.1% Vehicle
(nZ 205)
.0) 39 (19.4) 33 (16.1)
.4) 0 0
.1) 9 (4.5) 6 (2.9)
.2) 0 0
0 0
.8) 9 (4.5) 6 (2.9)
0 0
.6) 3 (1.5) 3 (1.5)
.9) 0 0
0 1 (0.5)
0 0
EAEZ treatment-emergent adverse event
OL 40, FEBRUARY 2014
209NEPAFENAC 0.3% TO PREVENT AND TREAT OCULAR INFLAMMATION AND PAIN ASSOCIATED WITH CATARACT SURGERYexception of 1 patient in the nepafenac 0.3% groupwho
reported hypersensitivity, none of the events that led to
discontinuation were considered by the investigators
to be treatment related. No deaths occurred during
the study. Ten patients experienced serious adverse
events, including 7 in the nepafenac 0.3% group and
3 in the nepafenac 0.1% group, none of which were
considered by the investigators to be treatment related.
Two patients each in the nepafenac 0.3% and nepa-
fenac 0.1% groups discontinued the study due to
nonfatal serious adverse events (1 report each of brain
edema, injury, cerebrovascular accident, and sepsis).
The most common ocular adverse event was
increased IOP, while the most common nonocular
adverse event was headache (Table 3). Two patients
experienced a change in IOP of 40 mm Hg or greater
during the study; 1 patient receiving nepafenac 0.3%
had a change of 43 mm Hg from a baseline value of
11 mm Hg, and 1 patient receiving nepafenac 0.1%
had a change of 56 mm Hg from a baseline value of
12 mm Hg. All instances of increased IOP and head-
ache were mild to moderate in intensity, resolved
with or without treatment, and were considered by
the investigators to be unrelated to the study drugs.
With the exception of 1 patient in the nepafenac 0.3%
group who discontinued due to elevated IOP, these
events did not result in patient discontinuations from
the study. No clinically relevant changes from baseline
were observed in the CDVA, IOP, dilated fundus pa-
rameters, or ocular signs.DISCUSSION
In this phase 3 randomized controlled study, once-
daily dosing with nepafenac 0.3% was as effective as
dosing 3 times daily with nepafenac 0.1% for the pre-
vention and treatment of ocular inflammation and
pain after cataract surgery. Furthermore, nepafenac
0.3% and nepafenac 0.1% were superior to their
respective vehicles for all efficacy endpoints, with
fewer treatment failures and more patients achieving
clinical cure. By day 14, 68.4% of patients treated
with once-daily nepafenac 0.3% were cured and
91.0% were pain free. The results in this study are
consistent with those in previous studies of nepafenac
0.1% 3 times daily,13,17–19 which found that nepafenac
0.1% was superior to its vehicle in terms of ocular
inflammation cure rates, pain-free rates, and clinical
successes in patients after cataract surgery.
The percentage of patientswho achieved clinical suc-
cess was higher in patients who received once-daily
nepafenac 0.3% than in those who received nepafenac
0.3% vehicle (P%.0264). This difference was observed
from as early as 1 day postoperatively and persisted
throughout the duration of the study on days 3, 7,J CATARACT REFRACT SURG - Vand 14. These findings are consistent with the mecha-
nism of action of nepafenac and the preoperative
dosing of nepafenac, which suppresses inflammation
at the time of surgical trauma. The higher concentration
of nepafenac 0.3% in the tissue before surgery is ex-
pected to inactivate COX enzyme activity to a greater
extent, reduce the magnitude of the inflammatory
response, and facilitate resolution of trauma-induced
inflammation. Similar findingswereobserved fornepa-
fenac 0.1% versus its control group, with significantly
more patients achieving clinical success from day 3.
The clinical success endpoint is an important indica-
tor that ocular inflammation has resolved to the point
that no further treatment is necessary. This is particu-
larly important at present because of the improve-
ments in cataract surgery over the past decades and
the related high patient expectations for rapid recov-
ery after surgery.9 Clinical success as measured in
this study is a practical, less subjective endpoint
because a single cell in the anterior chamber may be
seen in patients who have not had surgery and do
not have existing inflammation.23,24 Functionally,
because the clinical success endpoint allows some vari-
ability (trace, 0 to 5 cells) around the evaluation, it is
more likely that the patient will be categorized
correctly rather than forcing a distinction between
cleared and trace, when the appearance of 1 cell in
the slitlamp field may determine that difference.
The high clinical success rates with nepafenac 0.3%
once daily and nepafenac 0.1% 3 times daily are sup-
ported by the corresponding low number of treatment
failures. At day 14, nepafenac 0.3% once daily was
associated with the lowest rate of treatment failure.
Postoperatively, nepafenac 0.3% with once-daily
administration is expected to be more convenient for
patients, with the potential of improving dosing
compliance.25 This may be particularly important in
elderly patients, for whom compliance is a concern.26
Postoperative inflammation remains a key cause of
patient discomfort and delayed recovery after cataract
surgery.9 Nepafenac 0.3% dosed once daily was as
effective as nepafenac 0.1% 3 times daily and superior
to the nepafenac 0.3% vehicle for ocular inflammation
endpoints at day 14. Increased IOP is a common early
occurrence after cataract surgery,27,28 and the inci-
dences of increased IOP in the present study were
similar in the nepafenac 0.3% group and nepafenac
0.1% group (1.0% and 0.9%, respectively). The major-
ity of the reported cases of increased IOP occurred
early (on day 2 or day 3) and resolved with treatment
within 1 day. Furthermore, no clinically relevant
changes from baseline in CDVA, dilated fundus
parameters, or ocular signs were observed.
The above findings are supported by the overall
safety findings in this study. Nepafenac 0.3% wasOL 40, FEBRUARY 2014
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treatment-related adverse events. Overall, the
safety data for nepafenac 0.3% once daily and
nepafenac 0.1% 3 times daily were consistent with
results in previous clinical studies of nepafenac 0.1%
3 times daily.13,17–19 Nepafenac 0.3% used once
daily at a higher concentration had a safety
profile similar to nepafenac 0.1% used 3 times
daily in adult and elderly patients who had cataract
surgery.
This was a large randomized controlled double-
masked study of 2022 patients 65 years of age or older
that assessed the efficacy and safety of once-daily
nepafenac 0.3% for up to 14 days. The risk for cataract
increases with age, and age-related cataracts are
among the most common form.1 Although pharma-
cologic intervention in the study was controlled, the
investigators used their own standard surgical
methods on all patients. Therefore, slight differences
between the techniques and procedures used by cata-
ract surgeons were not addressed in this study; none-
theless, results showed very little variability. Further
studies are needed to assess the relative efficacy of
nepafenac 0.3% versus other topical NSAIDs after
cataract surgery.
Nepafenac 0.3% instilled once daily was as effective
as nepafenac 0.1% instilled 3 times daily for the pre-
vention and treatment of ocular inflammation and
pain after cataract surgery. Nepafenac 0.3% was well
tolerated, with a safety profile comparable to that of
nepafenac 0.1%. The once-daily dosing regimen of
nepafenac 0.3% may improve treatment outcomes
after cataract surgery through increased compliance
and reduced treatment burden.WHAT WAS KNOWN
 Nepafenac 0.1% dosed 3 times daily beginning the day
before surgery and for up to 14 days after cataract surgery
is safe and effective for reducing postoperative ocular
inflammation and pain.WHAT THIS PAPER ADDS
 The efficacy and safety profiles of nepafenac 0.3%
instilled once daily beginning the day before surgery
and for up to 14 days after surgery were comparable to
those of nepafenac 0.1% instilled 3 times daily for the
same duration.
 Nepafenac 0.3%, a new formulation of nepafenac with
once-daily dosing, decreases the treatment burden, which
could improve treatment compliance and therapeutic
outcomes.J CATARACT REFRACT SURG - VREFERENCES
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